Clinical Trial Update: Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with apatinib for radioactive iodine-refractory differentiated thyroid cancer; the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Radioactive Iodine-refractory Differentiated Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING